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According to the Centers for Disease Control and Prevention, 5.9% of the U.S.
population, or 15.7 million people have diabetes (Centers for Disease Contro~ 1998).
There are approximately 800,000 new cases of diabetes diagnosed each year (Centers for
Disease Contro~ 1998). Of the 15.7 million individuals with diabetes, 90%·95% have
type 2 diabetes (Centers for Disease ControL 1998). Major risk factors for developing
type 2 diabetes, formerly known as non-insulin dependent diabetes mellitus (NIDDM),
include older age, obesity, family history of the disease, and impaired glucose tolerance
(Centers for Disease Control, 1998).
Complications that stem from diabetes include heart disease, stroke, high blood
pressure, kidney disease, blindness, nervous system disease, and amputation (Centers for
Disease Control, 1998). The most recent report from the American Diabetes Association
indicated that the total cost of the disease is estimated at $98 billion (Centers for Disease
Control. 1998). Direct medical costs accounted for $44 billion, while indirect costs, such
as loss ofwork, disability, and early death accounted for $54 billion ofthe total cost of
illness (Centers for Disease Contro~ 1998). In an effort ro reduce costs and
complications associated with type 2 diabetes, one goal of current research is to identify
new treatments and methods for the prevention of the disease. Lifestyle modifications
such as increased physical activity and improved dietary practices are proposed to reduce
the incidence of type 2 diabetes by as much as 58% in individuals who are at high risk for
diabetes (American Diabetes Association, 2000).
Inadequate chromium status may be associated with exacerbating risk factors for
developing type 2 diabetes. Studies have shown that an inadequate chromium intake
leads to decreased insulin sensitivity and increased blood glucose concentration in
humans (Anderson, 1992). Impaired glucose tolerance and insulin sensitivity, which lead
to elevated insulin concentration, are risk factors for developing type 2 diabetes
(Anderson, 1992). Several controlled research studies have indicated that adequate
chromium intake improves glucose tolerance and reduces insulin concentrations required
to handle the uptake ofglucose into cells (Glinsmann & Mertz, 1966; Martinez et aI.,
1985; Anderson et aI., 1983; Anderson et al., 1991; Anderson, I997a; Guan et aI., 2000).
Other studies have shown no improvement in glucose tolerance or insulin sensitivity with
increased chromium intake (Abraham et aI., 1992; Trow et aI., 2000; Amato et a1., 2000).
Researchers continue to debate if chromium is effective as a preventive measure or a
treatment for those who already have diabetes, and the exact level of chromium required
to show a beneficial effect on glucose tolerance (Hellerstein, 1998).
Objectives
Developing treatments to prevent diseases such as type 2 diabetes will aid in
reducing both direct and indirect health care costs as well as improve the quality of life
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for individuals at risk for developing diabetes. The purpose of this study is to examine
the effects of twelve weeks ofchromium supplementation, at 200 meg/day as chromium
cWoride, on indicators of glucose metabolism in hyperglycemic men. The following
objectives were developed for this study:
1. Detennine the effects of twelve weeks of chromium supplementation on
fasting serum glucose concentrations in hyperglycemic men.
2. Determine the effects of twelve weeks ofchromium supplementation on
fasting serum insulin concentration in hyperglycemic men.
3. Determine the effects of twelve weeks ofchromium supplementation on three-
hour glucose tolerance curves in hyperglycemic men.
4. Determine the effects of twelve weeks of chromiwn supplementation on
glycosylated hemoglobin concentration in hyperglycemic
men.
5. Determine the effects oftwelve weeks ofchromium supplementation on
percent specific insulin binding in hyperglycemic men.
Null Hypotheses
The following null hypotheses were developed for this study:
1. There will be no statistically significant effect of twelve weeks
chromium supplementation on fasting serum glucose concentrations in
hyperglycemic men.
2. There will be DO statistically significant effect of twelve weeks
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chromium supplementation on fasting sen-1m insulin concentrations in
hyperglycemic men.
3. There will be no statistically significant effect of twelve weeks
chromium supplementation on three-hour glucose tolerance curves of
hyperglycemic men.
4. There will be no statistically significant effect of twelve weeks
chromium supplementation on percent glycosylated hemoglobin of
hyperglycemic men.
5. There will be no statistically significant effect of twelve weeks
chromium supplementation on percent specific insulin binding of
hyperglycemic men.
Assumptions
The following assumptions were made for this research:
1. It was assumed that the participants accurately filled out their one··week food
frequency questiormaire.
2. It was assumed that the participants took their supplements as directed.
3. It was assumed that the participants fasted for twelve hours befure blood was
drawn.
4. It was assumed that the participants did not change their diet or exercise
patterns over the course of the study.
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5. It was assumed that the participants did not take any other supplements
containing chromium over the coW"Se of the study.
6. It was assumed that the participants did not undergo events causing lifestyle
changes, such as medication consumption and surgical events.
Limitations
1. The one week food frequencies were limited by the participants' knowledge of
portion size and food composition.
2. An inadequate data base for chromium limited analysis of chromium content
of participants' diets.
3. The results of the study are relevant to this sample group limiting
extrapolation of results to the general population.
4. The results of this study are limited by outside factors affecting participants,
such as changes in medication and surgical events.
5. The results of the study are limited by the tendency for health conscious





According to the Centers for Disease Control and Prevention, 5.9010 of the U.S.
populat ion, or 15.7 million people have diabetes (Centers for Disease Control, 1998).
There are approximately 800,000 new cases of diabetes diagnosed each year (Centers for
Disease ControL 1998). Ofthe 15.7 million individuaJs with diabetes, 900/0-95% have
type 2 diabetes (Centers for Disease ControL 1998). Risk factors for developing type 2
diabetes include being over 40 years of age, overweight, physically inactive, having a
family history ofdiabetes or a prior history ofgestational diabetes, or impaired glucose
tolerance (Centers for Disease Control, 1998; American Diabetes Association, 2000).
Type 2 diabet~ is a disease characterized by insulin resistance (American Diabetes
Association, 2000). Tnsulin binding to cell surface insulin receptors enables a cell to take
glucose from the bloodstream. JrlSulin resistance means that insulin is not binding to its
receptors. Defects in insulin action result in high blood glucose concentrations due to the
cells' inability to remove glucose from the bloodstream (Centers for Disease Contro~
1998).
The most oommon procedme for diagnosing type 2 diabetes is a fasting plasma
glucose test (Centers for Disease ControL 1998). A diagnosis of diabetes requires a
twelve-hour fasting plasma glucose concentration to be greater than or equal to 126 rngIdl
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(Centers for Disease Contro~ 1998). A previous history ofexcessive thirst and urination,
unexplainable fatigue, constant hunger or weight loss, or a non-fasting plasma glucose
concentration greater than or equal to 200 mg/dl would be indicative oftype 2 diabetes
(Centers for Disease Contro~ 1998). A further means ofdiagnosing type 2 diabetes is an
oral glucose tolerance test. This procedure involves the consumption ofa glucose
tolerance beverage containing 75 g of dextrose dissolved in water (Centers for Disease
Contro~ 1998). Two hours after consumption ofthe beverage, two-hour plasma glucose
concentration is measured. A plasma glucose concentration greater than or equal to 200
mg/dl two hours after consuming a glucose tolerance beverage would be indicative of
type 2 diabetes (Centers for Disease Contro~ 1998).
Early diagnosis is essential to avoiding further complications of diabetes.
Complications that stem from diabetes include heart disease, stroke, high blood pressure,
kidney disease, blindness, nervous system disease, and amputation (Centers for Disease
Contro~ 1998). Heart disease death rates for adults with diabetes are two to four times
higher than heart disease death rates for adults without diabetes (Centers for Disease
Control, 1998). Stroke risk is two to four times higher for individuals who have diabetes
(Centers for Disease Contro~ 1998). Among those who have diabetes, an estimated 60%-
65% have high blood pressure (Centers for Disease Contro~ 1998). Approximately 40%
ofnew end-stage renal disease cases are individuals with diabetes (Centers for Disease
Contro~ 1998). Blindness associated with diabetic retinopathy is responsible for 12,000-
24,000 new cases ofblindness each year (Centers for Disease Control, 1998). Nervous
system diseases related to diabetes account for the majority of lower extremity
amputations (Centers for Disease Contro~ 1998).
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Complications that stem from diabetes account for much of the disease cost The
most recent report from the American Diabetes Association indicated. that the total annual
cost of the disease is estimated at $98 billion (Centers for Disease Contro~ 1998). Direct
medical costs accounted for $44 billion, while indirect costs, such as loss of work,
disability, and early death accounted for $54 billion of the total cost of illness (Centers
for Disease ControL 1998).
According to the World Health Orga.nization, ifcurrent trends continue, the
number of individuals worldwide with diabetes will increase from 140 million to 300
million by the year 2025 (World Health Organization, 2000). The development of
effective treatment and prevention programs is essential for reducing the costs and
complications associated with type 2 diabetes. Increased physical activity and weight
control are two important factors that influence the onset of type 2 diabetes (pi-Sunyer,
1996). Studies have shown that weight loss improves insulin sensitivity, and thus
improves glucose control (Pi-Sunyer, 1996; American Diabetes Association, 2000).
Improvement of dietary habits is a cost-effective way to reduce risk, and minimize the
complications associated with type 2 diabetes (Franz et al., 1995).
Chromium
Chromiwn (Cr) is a ushiny, hard, white metal, belonging to the fIrst series of
transition elements" (Ducros, 1992). Chromium can occur in various oxidation states,
ranging from -2 to +6 (Ducros, 1992). The most common oxidation states are 0, +2, +3,
and +6 (Ducros, 1992; Jeejeebhoy, ICJ99). Divalent (+2) chromium is ox.idized to
trivalent (+3) chromium by "simple exposure to air" and, therefore, "does not exist in
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biological systems" (Ducros, 1992). Hexavalent (+6) chromium can "readily penetrate
cells" at a rate perhaps 1000 times faster than trivalent chromium (Jeejeebhoy, 1999).
After penetrating the cell, hexavalent chromium is reduced to trivalent chromium
(Jeejeebhoy, 1999). The process ofreduction forms reactive oxygen intermediates that
react with DNA (Jeejeebhoy, 1999). The reaction between DNA and reactive oxygen
intennediates "is believed to mediate the genotoxic effects ofbexavalent chromium"
(Jeejeebhoy, 1999). Hexavalent chromium also "penetrates the mitochondria and
depresses oxygen consumption" (Jeejeebhoy, 1999). Hexavalent chromium is an
industrial polJutant that is ''very toxic to tissues because of its oxidizing properties"
(Jeejeebhoy, 1999). Trivalent chromium "diffuses slowly across the cell membrane" and
is the most stable form ofchromium (Jeejeebhoy, 1999). Trivalent chromium exists in
various forms, such as chromic oxide and chromic chloride (Jeejeebhoy, 1999). Trivalent
chromium is "the form ofCr found in foods and nutrient supplements" (Anderson et al.,
1997). This study utilized trivalent chromium in the form ofchromium chloride
hexahydrate (CrCb.6H20).
For this particular study, chromium's function of interest is enhancing insulin
sensitivity and maintenance ofglucose tolerance. Convincing evidence of chromium's
role in maintaining glucose metabolism comes from patients receiving total parenteral
nutrition (Vincent, 2000a; Brown et al., 1986). In one such case, a patient receiving total
parenteral nutrition (TPN) developed glucose intolerance (Brown et al., 1986). After a
series oftests and analysis of medical records, chromium deficiency was determined as
the cause (Brown et al., 1986). Subsequent supplementation ofchromium into the TPN
solution corrected the glucose intolerance (Brown et ai, 1986).
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Chromiwn is believed to maintain glucose metabolism LWUgh the activation of
insulin receptors (Vincent, 20008; Anderson, 2000). The proposed biochemical
mechanism tying chromium to insulin receptor activity Involves the oligopeptide
chromodulin, also known as Jaw-molecular weight chromium-binding substance
(Vincent, 2000a). Binding of insulin to insulin receptors triggers the movement of
chromium, "presumably in the form ofCr-transferrin", into insulin~depe.ndent cells
(Vincent,2000s). Once inside the cell, chromium binds to apochromodulin (Vincent,
2000a). Newly formed chromodulin binds to the insulin receptor, "further activating the
receptor kinase activity" (Vincent, 2000a). Increased kinase activity is believed to be due
to "'stabilization of the active conformation ofinsulin receptors" by binding of
chromodulin (Vincent, 2000b).
Before chromium can enter insulin-dependent cells, it must first enter the blood
stream. Although the exact mechanism of chromium absorption remains uncertain., it is
known that chromium is absorbed through the intestinal mucosa (Ducros, 1992; Vincent,
2000a). Factors affecting chromium absorption include "oxalate intake, iron and zinc
deficiency, and diabetes," which increase absorption (Jeejeebhoy, 1999). Factors that
decrease chromium absorption include phytate intake and aging (Jeejeebhoy, 1999).
Once absorbed, transferrin and albumin transport chromium (Ducros, 1992;
Vincent,2000a). Transport ofchromium via albumin occurs only after transferrin has
become saturated (Ducros, 1992). Varying amoWlts of chromium are transported to and
accumulate in the liver, soft tissue, spleen, and bone (DuCIOS, 1992). Chromium is




As trivalent chromium is poorly absorbe~ it is "difficult to determine whether
trivalent chromium itself is toxic once inside the cell" (Jeejeebhoy, 1999). Concern has
been expressed toward the '"validity of the cell culture studies reporting clastogenic
effects of Cr picolinate and extrapolating the results" to mammalian and "ultimately
human studies" (Anderson et al., 1997). In such a cell culture study, "the minimum value
where an effect was observed was several thousand-fold higher than any levels observed
in the blood ofhumans following Cr supplementation" (Anderson et aL, 1997; Sterns et
aI., 1995). Several studies involving both animals and humans have shown no toxic
effects from usage of chromium supplementation. One particular study fed pregnant
mice "up to 15 mg/kg per day trivalent chromium" (Jeejeebhoy, 1999; Danielsson et al.,
1982). Accumulation of trivalent chromium in fetal tissues "did not cause any
cytotoxicity in fetal mice" (Jeejeebhoy, 1999; Danielsson et al., 1982). As for human
clinical studies, in "19 randomized controlled trials in which individuals received
between 175 and 1000 mcg/day chromium for durations of between 6 and 64 weeks,
there was no evidence ofany toxic effects" (Jeejeebhoy, 1999). Perhaps discrepancies
between cell culture studies and animal and human studies regarding trivalent chromium
toxicity exist because in cell culture studies "protective mechanisms," such as
"absorption, transport, conversion to a useful form and/or mechanisms for the conversion
to a form that is nontoxic" have been removed or "minimized" (Anderson et aL, 1997).
Chromium's "essentiality in humans was documented in 1977" as the result of a
patient receiving inadequate long-term TPN (Anderson, 1997b; Jeejeebhoy et aI., 1977).
Symptoms, such as glucose intolerance, were corrected upon addition of chromium to the
TPN solution (Jeejeebhoy et aJ., 1977). Signs and symptoms of chromium deficiency
I'
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that "are routinely observed in the general population" include impaired glucose
tolerance, filsting hyperglycemia, glycosuria., hypoglycemia, elevated circulating insulin,
decreased insulin receptor number, decreased insulin binding, decreased lean body mass,
elevated percent body fat, and increased ocular pressure (Anderson.. 1997b). As research
interest grows in identifying subclinical deficiency states as causing many oftoday's
health problems, more a.ttention will be focused on the importance of maintaining optimal
health through the consumption of a well-rounded diet, and supplementation when
necessary.
Foods containing whole grains are considered a good source ofdietary chromium
(Anderson et at, J992). Organ meats, as well as "cheese, mushrooms, various
condiments and spices" are considered foods that provide ''relatively high amounts of
chromium" (Groff and Gropper, 2000; Khan et aI., 1990; Kumpulaineu, J992).
When our study began in May of2000, the estimated safe and adequate daily
dietary intake for chromium was 50-200 meg/day for adults (National Research Council.,
1989). According to newly released Dietary Reference Intakes, an Adequate Intake of 35
mcg/day for men and 25 meg/day for women has been set for chromium consumption
Onstitute of Medicine, 2001). The new values were released in January 2001, well after
our study had been completed. Due to the lack ofavailable data pertaining to "adverse
effects remtting from chronically high intake of the chromium contained in
supplements,n 00 Upper Limit was set (Instrtule of Medicine, 2001).
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Chromium and Glucose Tolerance
The relationship between chromium and glucose tolerance dates back to a 1959
study involving rats. The study demonstrated a ')-equirement for chromium to maintain
normal glucose tolerance in rats" (Mertz, 1993; Schwarz and Mertz, 1959). Research has
continued to try and discover the link. between chromium and glucose tolerance. Studies
have been conducted involving, among other species, horses, pigs, rats, and humans.
Significant evidence has yet to be revealed that will whole-heartedly support beneficial
effects of chromium on maintenance of glucose tolerance. Supporters point to cases
where individuals receiving total parenteral nutrition (TPN) have developed symptoms,
such as hyperglycemia, glycosuria, peripheral neuropathy, and unexpected weight loss,
that were corrected with the addition of chromium to TPN solution (Brown et al., 1986;
Jeejeebhoy et aL, 1977; Freund et a1., 1979). Detractors point to studies involving non-
obese healthy humans, and patients with Type 2 diabetes that have shown no beneficial
effects from chromium supplementation (Amato et ai, 2000; Trow et aI., 2000).
Other researchers argue that people are missing the point. Researchers such as
these argue that chromium is effective at preventing the onset of further glucose
intolerance by regulating insulin sensitivity before the individual develops type 2 diabetes
(Anderson, 1992). Chromium would not be as effective as a treatment for type 2 diabetes
as it would a preventive measure (Anderson, 1992). Likewise, a heahhy individual with
adequate glucose tolerance and insulin sensitivity would not show benefits from
consuming extra chromium in the form of supplementation, as it wuuJd appear that they
are getting a sufficient amount from their diet (Anderson, 1992). Studies that support
some of these claims have shown that chromium is beneficial for people who have
13
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elevated plasma insulm with no signs of elevated plasma glucose (Riales and Albrink,
1981). A study such as this may suppon the claim that chromium supplementation is an
effective preventive measure against the onset of type 2 diabetes. These articles and
others will be discussed in this section of the literature review.
Researchers who believe in chromium's ability to maintain glucose tolerance
point to TPN patients as providing evidence to support their belief. A 63 year old woman
with an ileocolostomy was on TPN for 6 !I,. months when she presented with "disturbed
glucose metabolism, hyperglycemia, and glycosuria" (Brown et aI., 1986). After ruling
out other causes, "the assumption that chromium deficiency was responsible for glucose
intolerance" led to an infusion of chromium chloride to her TPN solution (Brown et al.,
1986). For a two week period, 200 meg of chromium chloride was added to the TPN
regimen daily (Brown et a1., 1986). During the first five days of added chromium
supplementation, extra insulin that was added to the TPN solution to combat the glucose
intolerance "was gradually withdrawn" (Brown et al., 1986). After addition of the
chromium chloride and withdrawal of insulin, the patient's serum glucose dropped to 169
mg/dI from well over 200 rngIdl and the glycosuria ended (Brown et al., 1986). The
patient was eventually released from the hospital and remained on home TPN containing
32 meg chromium daily (Brown et aI., 1986).
Another patient who had a complete bowel resection and was on TPN for 5
months developed "severe glucose intolerance, weight loss, and a metabolic
encephalopathy-like confusional state" (Freund et al., 1979). The patient's "serum
chromium level was 0.5 mcg/dt (0.005 ppm), the lowest level of normal (nonnal, 0.5 to
9.0 mcg/dl or 0.005 to 0.09 ppm)" (Freund et aL, 1979). The patient began to receive 150
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meg of chromium chloride daily in her TPN solution (Freund et ai, 1979). A few days
later, extra insulin (20-30 units/day) that had been added to her TPN prior to chromium
supplementation was removed (Freund et aI., 1979). When the patient was receiving the
20-30 units of insulin per day, her blood glucose level varied "between 72 to 4{)O mg/dl,
with fluctuations as high as 581 mgldl and erratic spilling ofglucose in the urine" (Brown
et aI., 1986). After the addition of chromium chloride and removal of insulin from her
TPN solution, the patient's blood glucose ''was maintained at around 130 to 140 mgldl
(range, 73 to 200 mg/dl), with no spilling of glucose in the urine" (Freund et aI., 1979).
The patient's '-'encephalopathy cleared completely, and she started gaining weight"
(Freund et aI., 1979).
An earlier case of chromium deficiency diagnosed in a patient receiving TPN
involved a woman who "underwent a complete enterectomy" (Jeejeebhoy et aI., 1977).
She was on TPN for 3 years when she developed ''weight loss, neuropathy, and glucose
intolerance" (Jeejeebhoy et ai., 1977). After a clinical neurological examination, the
"fIndings were considered to be consistent with a diabetic neuropathy" (Jeejeebhoyet
aI., 1977). Insulin was administered in order to control glucose intolerance. After having
"45 units of insulin added to each daily infusion", the patient was still below her average
weight and the neuropathy ''was fOW1d to have persisted despite maintenance of near
euglycemia" (Jeejeebhoy et al., 1977). Insulin was discontinued and plasma glucose
levels "taken at midnight varied between 207 and 265 mg/dl" (Jeejeebhoy et aI., 1977).
Since "plasma insulin concentrations were normal and the insulin response in the
intravenous glucose tolerance tests had been only very mildly reduced, other causes of
glucose intolerance were sought" (Jeejeebhoy et al., 1977). Chromium levels "in blood
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and hair were found to be low, and a balance study was strongly negative" (Jeejeebboy et
al., 1977). Chromium deficiency was considered, and "it was decided to check the effect
of infusing 250 meg of chromium daily for 2 weeks" (Jeejeebhoy et aI., 1977). After two
weeks of chromium supplementation via TPN solution, 2 hour postinfusion plasma
glucose concentrations "varied between III and 118 mg/dl without added insulin"
(Jeejeebhoy et aI., 1977). Plasma glucose concentrations taken at midnight without
insulin ''varied between 177 and 196 mgldl" which were "significantly lower (P<0.05)
than levels observed before the administration of chromium (207 to 265 mg/dl)"
(Jeejeebhoy et aI., 1977). After continued chromium supplementation the neuropathy
''was no longer detectable either clinically or by nerve conduction studies" (Jeejeebhoy et
aI., 1977). The patient maintained a sense of well being, nonnal plasma glucose, and no
neuropathy "00 a daily infusion of chromium amounting to 20 meg/day" (Jeejeebhoy et
aI., J977).
Case studies ofpatients receiving TPN demonstrate the deleterious effects of
chromium deficiency. Glucose intolerance, decreased insulin sensitivity, and
neurological problems are three symptoms associated with chromiwn deficiency. These
symptoms were clearly corrected through the introduction of supplemental chromium to
their TPN solutions.
Studies have been conducted revealing that TPN patients are not the only
individuals at risk for potential chromium deficiency, Anderson et 81. conducted a study
on free-living individuals consuming controlled low-chromium diets (Anderson et ai,
1991). This 14-week crossover study involved 17 subjects (11 females, 6 males) aged
22-65 years. Screening procedures separated the subjects into two groups,
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hyperglycemic (90-min glucose values> 5.56 but < 11.1 mmollL) and control (90-min
glucose values < 5.56 nunollL) (Anderson et aL, J991). People with diabetes or
"clinically significant abnormal blood or urine profiles were excluded from the study"
(Anderson et ai, 1991). During the study all participants consumed a low chromium diet
containing less than 20 meg per day (Anderson et al., 1991). After a 4 week pretest
period, "subjects received tablets containing either 200 meg Cr as chromium chloride or
placebo" (Anderson et aI., 1991). At week 10 the subjects ''received !.he opposite tablets"
(Anderson et aL, 1991).
The results of this study favored chromium supplementation for those individuals
who were in the hyperglycemic group. There was no significant difference in the glucose
tolerance or insulin values for the control group during the placebo period and their
values "remained constant during the chromium-supplementation period" (Anderson et
al., 1991). There was a significant difference in glucose tolerance and insulin values for
the hyperglycemic group (Anderson et aI., 1991). Their values deteriorated as time went
on while consuming the low chromium diet (Anderson et al., 1991). However, the sum
of the 0 to 90 and 0 to 240 minute glucose values "were significantly lower for the
hyperglycemic subjects after chromium supplementation [26.5 and 39.4 mmoVL
respectively] then for comparable placebo values [30.0 and 42.9 mmollL respectively]"
(Anderson et al.• 1991). Insulin values also significantly improved for the hyperglycemic
group while receiving chromium supplementation (1320 and 1703 rnmoVL respectively)
when compared to values obtained during the placebo period (1787 and 2285 mmoVL
respectively) (Anderson et al., 1991). Th.is study showed the beneficial effects of
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chromium supplementation for hyperglycemic individuals consuming a low chromium
diet.
Another study that demonstrated beneficial effects of chromium supplementation
on glucose concentrntions involved 76 free-living individuals (48 men and 28 women)
aged 21-69 years (Anderson et al., 1983). This double-blind crossover study lasted for 6
months and involved taking ofa placebo and a 200 meg supplement ofchromium
chloride (Anderson et at, 1983). There were two experimental periods lasting 3 months
each (Anderson et at, 1983). During the first three-month period. one group received
200 mcg of chromium chloride per day and the other group received a placebo (Anderson
et a1.. 1983). During the second three-month period the group that had been receiving the
chromium took the placebo and vice versa (Anderson et aJ., 1983). At the beginning of
the study, 20 of the 76 subjects "had serum glucose concentrations greater than or equal
to 100 mgIdl 90 minutes after a glucose challenge (l g glucose per kilogram of body
weight)" (Anderson et aI., 1983). According lo the results of this study, "chromium
supplementation significantly decreased (P<O.05) the 9O-minute glucose concentrations
of these subjects from 135 ±9 to 116 ±11 mg/dl" (Anderson et aI., 1983). The fasting
serum glucose concentrations of these subjects also significantly (P<O.05) decreased
"from 90 ± 3 mg/dl to 80 ±2 and 84 ±2 mgIdl after 2 and 3 months Cr supplementation,
respectively" (Anderson et at, 1983). Serum insulin values did not signillcantly decrease
for these subjects (Anderson et aI., 1983). However, as the researchers involved with this
study concluded. "the insulin in the serum appeared to be more effective ... following Cr
supplementation" and an "increase in insulin sensitivity would be a prerequisite to
reduced circulating levels" (Anderson et aI.• 1983).
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Other studies are not as quick to make a positive association between chromium
supplementation, glucose tolerance, and insulin sensitivity. However, what seems to be
the underlying characteristic of these studies is that they either involved people who were
already diagnosed with diabetes, or were healthy and nonobese. For example, one such
study looked at the effects ofchromium supplementation on glucose tolerance and
plasma insulin levels in patients with type 2 diabetes (Trow et aI., 2000). This
uncontrolled, pilot study used 12 free-living patients with type 2 diabetes (Trow et aI.,
2000). The subjects took a chromium rich yeast capsule containing 100 meg of
chrorniwn per day for 8 weeks. According to their results, ''fasting glucose
concentrations and glucose area under the curve profiles did not alter significantly post
supplementation with the chromium rich yeast (Trow et al., 2000). There were also DO
significant changes in insulin concentrations (Trow et aI., 2000). The researchers pointed
out that it was "possible that an effect could have been observed with a larger study
group" (Trow et aJ., 2000).
Another study that obtained results casting doubt on the beneficial effects of
chromium involved healthy, nonobese, older men and women (Amato et ai., 2000). This
was "a randomized, double- blind., placebo-controlled study with 19 subjects (9 men and
10 women), aged 63-77" (Amato et a1., 2000). The subjects were given "either
chromium picolinate, 1000 meg/d., or a placebo for 8 weeks" (Amato et al., 2000).
Amato et al reported that "chromium pioolinate supplementation alone does not appear
to improve insulin sensitivity ... in nonobese. healthy men and woman ofadvanced age"
(Amato et a1. , 2000). The researchers from this study stated that their results "cast doubt
on the role ofchromium picolinate supplementation for the maintenance of glucose
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homeostasis in healthy men and women ofadvanced age" (Amato et al., 2000). What has
been said in the past is that chromium "improves glucose and insulin function of people
with varying degrees of glucose intolerance that range from hypoglycemia to
uncontrolled steroid diabetes with no detectable effects on glucose and insulin in people
with good glucose tolerance" (Anderson, 2000). To state that this study by Amato et aI.
might cast doubt on the beneficial effects of chromium supplementation is a bit
premature since the study dealt with healthy, nonobese individuals.
A study with similar results brought a different conclusioD. A study by
Offenbacher et aL that involved "twenty-three healthy, weU nourished, free-living elderly
volunteers" found no significant changes in glucose tolerance and insulin associated with
10 weeks of supplementation with "5 g brewer's yeast, 200 meg C~~ as chromic chloride
(erCh), or placebo" (Offenbacher et aJ., 1985). However, rather than stating that their
fmdings cast doubt on the beneficial effects of chromium supplementation, the
researchers stated that this study "suggests that age per se is not a factor leading to
chromium deficiency" (Offenbacher et al., 1985). This sentiment coincides with
Anderson, who stated a heahhy individual with adequate glucose tolerance and insulin
sensitivity would not show benefits from consuming extra chromium in the form of






This was a double blind study that followed a pretest-posttest control group
experimental design. Two groups were involved with this study, a control group
receiving a lactose placebo, and a treatment group receiving a supplement containing 200
mcg chromium as chromium cWoride in lactose. Two data collections included a
baseline pretest collection at week zero and a posttest collection after twelve weeks of
supplementation.
Participants
The Oklahoma State University Institutional Review Board approved this study
for human subject research (Appendix A). Participants were solicited via flyer through
campus wide mailing, newspaper ads, and local posting of flyers throughout the
Stillwater area (Appendix B). Male participants were solicited for screening if they felt
they had or met one or more ofthe criteria that increased risk for diabetes, such as having
a family history of diabetes, or being overweight or over forty years ofage. Participants
were screened for fasting blood glucose concentrations less than 126 mg/dl, and two-hour
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serum glucose concentrations between J30 mgldl and 199 mg/dl foUowing a 75 g oral
glucose challenge (American Diabetes Association, 2000).
Supplement Preparation
Supplements for trus study were prepared in the Department ofNutritional
Sciences laboratory at Oklahoma State University. A gelatin capsule filler machine
(Quanterron., Inc., Burnsville, MN) was used to fill number two gelatin capsules
(Apothecary Products Inc., Minneapolis, MN).
On average, placebo capsules contained 0.24 goru.s.p. grade lactose
monohydrate (Spectrum Chemical Mfg. Corp., Gardena, CA). The chromium
supplement mixture consisted of2.0502 g ofU.S.P. grade CrCh.6H20 (Professional
Compounding Centers of America, Inc. Houston, IX) and 477.95 g lactose. so that 0.24 g
of chromiwn/lactose supplement mixture contained 200 meg of chrorruurn as
CrCh.6H20. lbe lactose and CrCh.6H20 were mixed for twenty-four bours in a ball
mixer (U.S. Stoneware. East Palestine, OH) to ensure that the CrCh.6H20 was mixed
evenly with the lactose. Eight O. I g samples were randomly taken from the chromium
and placebo mixtures, four from the chromium supplement mixture and four from the
placebo mixture. Samples were wet and dry ashed using a modification of the Hill et al
method (Hill et aI., 1986). Samples were then analyzed for chromium content using an
atomic absorption spectrophotometer (Model 5100 PC, Perkin-Elmer Corp., Norwalk,
CT). The average analyzed chromium content of the placebo was -0.484 meg/g. The
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average analyzed cbromiwn content of the chromium supplement mixture was 658.3
meg/g. The capsule free weigbt oftbe supplement mixture was adjusted to 0.3038 g so
that each capsule would contain 200 mcg chromiwn, as chromium chloride hexahydrate.
Data Collection
Screening
In March 2000 participants came to the Student Health Center on the campus of
Oklahoma State University after a twelve-hour fast. Participants were instructed to drink
water during the fast to ensure an easier blood draw. At the screening, participants
signed an informed consent for the screening (Appendix C). A HemoCue B-Glucose
Photometer (HemoCue Inc., Mission Viejo, CA) analyzed a finger-prick fasting blood
sample. If the fasting blood glucose concentration was greater than or equal to 126 mg/dl
participants were excluded from the study and referred to a doctor from the Student
Health Center. Panicipants with fasting blood glucose concentrations lower than ]26
mg/dl had a fusting blood sample taken by a licensed phlebotomist in a 6 mJ Vacutainer
serum tube (Franklin Lakes, NJ). Participants were then given a Glucose Tolerance
Beverage containing 75 g ofdextrose (Appendix D). Following consumption of the
beverage, blood samples were taken at 120 minutes in 6 mt Vacutainer serum tubes
(Franklin Lakes, NJ).
While participants waited for blood draw, they completed a health questionnaire
(Appendix E) and heights and weights were recorded. Participants' heights were
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measured while standing erect with heels together and back against a wall Heights were
measured from a scaled ruler taped to the wall. Participants' weights were measured with
a battery-powered scale. Body Mass Index (BMl) was calculated for each participant
based on the equation.: BMJ = body weight (kg) I height (m2) (Meisler and St. Jeor,
1996). After the final blood draw, participants were provided with nutritional support.
After laboratory analysis of fasting and two-hour serum glucose concentrations,
participants were contacted by telephone and given results. Participants with two-hour
serum glucose concentrations between 130 mgldl and 199 mgldl were invited to continue
participation in the study. Panicipants with two-hour serum glucose concentrations
greater than or equal to 200 mgldl were informed they could not continue with the study
and should consuh a physician. Written copies of laboratory results were mailed to all
participants.
Twenty individuals who qualified for the study and volunteered to participate
were matched pair-wise based on their fasting serum glucose, two-hour serum glucose,
age, and BM! and placed into two groups. Ten participants were placed in each group.
The groups were randomly assigned as treatment and placebo. The assignation of groups
as treatment or placebo was double blind.
Baseline Collection
In May 2000 participants came to the Student Health Center on the campus of
Oklahoma State University after a twelve-hour fast. Participants were instructed to drink
water during the fast to ensure an easier blood draw. At the baseline collection.,
participants signed an informed consent for the study (Appendix F). A licensed
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phlebotomist drew a fasting blood sample in a 10 m1 Vacutainer tube containing sodium
heparin and a 10 mI Vacutainer serum tube (Franklin Lak~ NJ)- Participants were then
given a Glucose Tolerance Beverage containing 75 g of dextrose (Appendix D).
FoUowing consumption of the beverage, blood samples were taken at 30. 60, 120, and
180 minutes in 6 ml Vacutamer serum tubes for detenninations requiring serum (Franklin
Lakes. NJ).
Participants were instructed on how to fill out a seven-day food frequency
questionnaire (Appendix G). While participants were waiting for blood draws, they
completed the seven-day food frequency questionnaire, and height and body weight was
recorded.. Participants' heights were measured while standing erect with heels together
and back against a wall. Heights were measured from a scaled ruler taped to the waU.
Heights were measured to check for consistency with the screening heights. Participants'
weights were measured with a battery-powered sca.le. The participants were also given
the first four-week supply of the randomly assigned supplement and instructed to take
one capsule daily with food. Six extra capsules were added to each four-week supply.
Remaining capsules were counted at the end ofeach four-week period to monitor for
compliance. Following the final blood draw, participants were provided nutritional
support. The second and third four-week supplies of supplements were delivered to the
participants on a monthly basis. Participants received $150.00 for their participation in
the baseline data collection.
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Post-data Collection
In August 2000, at the end of twelve weeks supplementation, subjects returned
after a twelve-hour fast to the Student Heahh Center on the campus ofOkJahoma State
University for the posttest data colle<:tion. A licensed phlebotomist drew a fasting blood
sample in a 10 ml Vacutainer tube containing sodium heparin and a 10 ml Vacutainer
serum tube (Franklin Lakes, NJ). Participants were then given a Glucose Tolerance
Beverage containing 75 g ofdextrose (Appendix D). Following consumption of the
beverage, blood samples were taken at 30, 60, 120, and 180 minutes in 6 rn1 Vacutainer
serum tube for determinations requiring serum (Franklin Lakes, NJ). Participants were
instruCled on how to fill out a seveD~day food frequency questionnaire (Appendix G).
While participants were waiting for blood draws, they completed the seven-day food
frequency questionnaire, and body weight was recorded. Following the fmal blood draw,
participants were provided nutritional support. Participants received $150.00 for their
participation in the posttesl data collection.
Blood Handling
The same blood handling techniques were followed for both baseline and posttest.
data ooJlections. Fasting heparin tubes were inverted and set on ice for thirty minutes. At
the Nutritional Sciences laboratory, two 0.5 m1 whole blood samples were transferred
from the fusting heparin tubes into 0.5 ml plastic storage tubes. The tubes were covered
with parafi.lm and stored at -20°C foJ' future analysis of glycosyJated hemoglobin
concentration. Erythrocyte membrane ghosts were prepared from the remaining fasting
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hepari.rUzed blood samples using a method developed by Dodge et al. (Dodge et al.•
1963). Erythrocyte ghosts were stored at -70DC fur futme analysis ofpercent specific
insulin binding and protein concentration.
Fasting, 30,60, 120, 180 minute serum tubes were placed on ice until
centrifugation at the Nutritional Sciences laboratory. The serum tubes were centrifuged
at 4,000 rpm for 30 minutes in a Jouan Inc. CR3I centrifuge. Serum was transferred with
transfer pipenes into individual 0.5 ml plastic storage tubes. Tbe storage tubes were




Whole blood glycosylated hemoglobin concentrations were determined using
Roche HbAlc kit number 075563 (Roche Diagnostic System, Inc., Somerville, NJ) on a
FARA clinical analyzer (COBAS FARA, Roche Diagnostic System, Inc., Montclair, NJ).
Calibration factors and control materials available from Roche Diagnostic Systems Jnc.
were used for quality control to ensure validity and reliability of the testing procedure.
Serum Glucose
Serum glucose concentrations were determined using Roche kit number 47383
(Roche Diagnostic Systems Inc., Somerville, NJ) on a FARA clinical analyzer {COBAS
27
Protein Concentration of Erythrocyte Ghosts
Protein concentrations of erythrocyte ghost samples were determined using BIO-
RAD protein assay kit number 500-001 (Los Angeles, CAl on a spectrophotometer
(Beckman. DU 640 Spectrophotometer). A standard curve of control samples was used
to ensure validity and reliability of the testing procedure.
Food Frequency Questionnaire Analysis
The seven-day food frequency questionnaires were used to monitor the
participants' dietary intake (Eel<. ct a1., 1991). The questionnaire was a modified version
of Willett's one-year food frequency questionnaire that was tested for reliability and
validity (Eck et al., 1991). The questionnaires were analyzed using the Food Processor
Plus Program (version 7.11. ESHA Research., Salem., OR). The same food codes were
used for all participants' entries. Food frequency questionnaires were analyzed to
monitor for changes in participants' diets.
Data Analysis
Data were analyzed using the Statistical Analysis System (SAS) for repeated
measures and least squared means (SAS Inst. lnc., Cary. NC, 1989). The level of
significance was set at P':::::: 0.05. Effect of the independent variable, chromium
supplementation, on the dependenl variables, fasting serum glucose, fasting serum
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Four participants were excluded from the data analysis. Two participants
received 100 g of dextrose rather than the 75 g dose they were supposed to have received
at the posttest collection. A third participant underwent open-heart surgery. A fourth
participant lost a substantial amount of weight after changing medications. These four
participants experienced events outside the realm of focus for this study. There were two
participants from each group therefore the groups remained even. Data from 16
participants. 8 from the chromium group and 8 from the placebo group, were analyzed for
this study.
Age
There was no significant difference between the mean age of the participants in
the two groups at baseline (Table t). The mean age of the chromium group was 46 ± 4
years, while the mean age of the placebo group was 49 ±4 years (Table)).
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Weight
Repeated measures analysis did not show a significant time by group interaction
for total body weight (fable 2). The mean total body weights of the chromium group at
baseline and posttesl were 245 ± 15 lbs. and 246 ± 14Ibs., respectively (Table I). The
mean total body weights of the placebo group at baseline and posttesl were 236 ±161bs.
and 237 ± 17 Ibs., respectively (Table 1). Repeated measures analysis showed a
significant group effect (Table 2). The mean total body weight of the placebo group was
9 Ibs. heavier than the chromium group at baseline and posttest.
Body Mass Index
Repeated measures analysis did not show a significant time by group interaction
for body mass index (EM!) (Table 2). The mean BMI ofthe chromium group was 35 ± 2
kglm2 at baseline and posttest (Table 1). The mean BMl of the placebo group was 32 ± 2
kglm2 at baseline and posttest (Table 1). Repeated measures analysis showed a
significant group effect (Table 2). The mean BMI of the chromium group at baseline and
posttest (35 ±2 kglm2) was 3 kg/m2 greater than the mean BMI of the placebo group at
baseline and posttest (32 ±2 kglm2). According to the 2000 Dietary Guidelines for
Americans, a BMI greater than 30 kglrn2 refers to obesity (United States Department of
Agriculture, 2000). The study participants were not body builders or extremely thin
giants, so the classification ofobese fits both groups.
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Dietary Intake
Repeated measures analysis did not sbow a significant time by group interaction
for dietary intake (Table 3). Repeated measw-e:s analysis showed a significant time effect
for total kilocalorie, carbohydrate, and fiber intakes (Table 3). The mean total kilocalorie
intakes for both the chromium and placebo groups were higher at baseline than al posttest
(Table 4). The mean total carbohydrate intakes for both the chromium and placebo
groups were rugher at baseline than at pasttest (Table 4). The mean total fiber intakes for
both the chromium and placebo groups were higher at baseline than at posttest (Table 4).
According to the 1977 Dietary Goals for the United States, which was issued by
the U.S. Senate Select Committee on Nutrition and Human Needs, participants oftrus
study did not consume the necessary nutrient quantities. In order to meet the goals set
forth by the Committee, American diets should be proportioned in such a way that 58%
of Iota! kilocalories come from carbohydrate, 12% of tota) kilocalories come from
protein, and less than 3~1o of tota! kilocalories come from fat (Select Committee on
Nutrition and Human Needs, 1977). The percentages of kilocalories coming from
carbohydrate for the chromium group at baseline and postlest were 5) % and 49%,
respectively. The percentages of kilocalories coming from carbohydrate for the placebo
group at baseline and posttest were 48% and 47%, respectively. Therefore the chromiwn
and placebo groups were below the recommended dietary intake for carbohydrate
consumption The percentages of kilocalories coming from protein for the chromium
group at baseline and posttest were 15% and 17%, respectively. The percentages of
kilocalories coming from protein for the placebo group at baseline and posttest were 15%
and 17%~ respectively. Therefore the chromium and placebo groups were above the
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recommended dietary intake for protein consumption. The percentages ofki.localories
coming from fat for the chromium group at baseline and posttest were 35% and 32%,
respectively. Therefore the chromium group was above the recorruncnded dietary intake
for fat consumption. The percentages of kilocalories coming from .fut for the placebo
group at baseline and posttest were 29010 and 30%, respectively. Therefore the placebo
group consumed the recorrunended dietary intake for fat consumption.
Serum Glucose
Repeated measures analysis did not show a significant time by group interaction
for serum glucose concentration in response to an oral glucose tolerance test (OGTI)
(Table 5). Repeated measures analysis showed a significant time effect for serum
glucose concentralion in response to an oral glucose tolerance test (Table 5), which was
expected since serum glucose concentrations naturally change over time during W1
OGTT.
At baseline, both groups had mean fasting serum glucose concentrations
indicative of impaired glucose tolerance (fasting glucose concentrations ~ll 0 mg/dl but
<126 rng/dl) (Wallach, 2000). The mean fasting serum glucose concentration for the
chromium group at baseline was 116 ±7 mgldl (Table 6). The mean fasting serum
glucose concentration for the placebo group at baseline was 128 ±8 mg/dl (Table 6). At
baseline, both groups had two-hour serum glucose concentrations indicative of impaired
glucose tolerance (two-hour glucose concentration following an OGTT ~140 mgIdl but
<200 mg/dl) (Wallach, 2000). The mean two-hour serum glucose concentration for the
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chromium group at baseline was 150 ± 16 mg/dl (Table 6). The mean two-bour serum
glucose concentration for the placebo group at baseline was 167 ±15 mg/dJ (Table 6).
At posttest, the mean fasting serum glucose concentration for the chromium group
was 106 ±5 mg/dl (Table 6). While this concentration was below the 110 mgIdl
concentration that is indicative of impaired glucose tolerance, it was not a significant
difference. At posttest, the mean fasting serum glucose concentration for the placebo
group was 120 ± 10 rng/dl (Table 6). At postlest., both groups still had two-hour serum
glucose concentrations indicative of impaired glucose toJerance (two-hour glucose
concentration following an OGTT ~140 rng/dl but <200 mg/dl) (Wallach, 2000). The
two-hour serum glucose concentration for the chromium group at posttesl was 150 ± 16
mg/dl, which was still above the reference concentration of 140 mg/dl (Table 6). The
two-hour serum glucose concentration for the placebo group at posttest was 140 ±12
mg/dl (Table 6).
Serum Insulin
Repeated measures analysis did not show a significant time by group interaction
for serum insulin concentration in response to an OGTf (Table 7). Repeated measures
analysis showed a significant time effect for serum insulin concentration in response to
an OGTI (Table 7), which was expected since serum insulin concentrations naturally
change over time during an OGTT. Both groups experienced a reduction in their serum
insulin concentrations from baseline to posnest OGTf (Table 8).
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Glycosylated Hemoglobin
Repeated measures analysis did not show a significant time by group interaction
for mean percent glycosylated hemoglobin (Table 9). Repealed measures analysis
showed significant group and time effects for mean percent glycosylated hemoglobin
(Table 9). Due to the lack of a significant time by group interaction, there was no
adjustment for covariance. The mean percent glycosylated hemoglobin of the chromium
group at baseline was 5.6 ±0.1 % (Table 10). The mean percent glycosylated hemoglobin
of the placebo group at baseline was 6.0 ± 0.1 % (Table 10). The mean percent
glycosylated hemoglo bin of the chromium group at posttest was 5.9 ±0.1 % (Table 10).
The mean percent glycosylated hemoglobin of the placebo group at posrtest was 6.4 ±
0.2% (fable 10). At baseline and pretest the mean percent glycosylated bemoglobin for
both groups fell within the 4% to 8% range associated with "persons without diabetes"
(Lee & Nieman, 1996).
Percent Specific Insulin Binding
Repeated measures analysis did not show a significant time by group interaction
for mean percent specific insulin binding (Table 9). Repealed measures analysis showed
a significant time effect for mean percent specific insulin binding. The mean percent
specific insulin binding/I 00 meg of protein for the chromium group at baseline was and
1.7 ±0.2 (Table 10). The mean percent specific insulin binding/lOO meg protein for the
placebo group at baseline was 2.0 ± 0.1 (Table IO). The mean percent specific insulin
binding/LOO mcg ofpfotein for the chromium group at posttest was and 1.4 ±0.2 (Table
10). The mean percent specific insulin binding/l 00 meg protein for the placebo group at
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posttest was 1.1 ± 0.1 (Table 10). Values for percent specific insulin binding/loo mcg
protein from other studies range from 0.93% to 2.51 % for healthy participants (Bhathena
et aI., 1989; Bhathena et al., 1995).
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Table I: Mean age, weight.. and body mass index at baseline and after 12 weeks of
supplementation with CrCh (experimental) or placebo (control)·
Experimental (n=8) Control (n=8)
Baseline Posttest Baseline Posttest
Weight (lbs.) 245 + 15 246 + 14 236 + ] 6 237 + ] 7
Body Mass Index (kg/m1) 35 + 2 35 + 2 32+2 32 + 2
Age (year)
-
46 + 4 49 +4
• Values are mean ± SEM
Table 2: Analysis of variance summary table for weight, and body mass index after
12 weeks supplementation with CrCh (experimental) or placebo (control)"
Source of Variance F value Probability




code (supp) 186.60 < 0.0001·
supplement 127.09 < 0.0001"
Body Mass rndex time 0.60 0.4510
supp*time 0.01 O.90Rl
code (supp) 201.38 0.0001·
-
·Significance at p:s 0.05
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Table 3: Analysis ofvariance summary table for kilocalorie, protein, carbohydrate, fiber,
and fat intakes after 12 weeks supplementation with Cn:h (experimental) or
placebo (control)*


























code (supp) 1.40 0.2700
·Significance at p S 0.05
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Table 4: Mean kilocalorie, protein, carbohydra1e, fiber~ and fat intakes at baseline and
after 12 weeks of supplementation with erCh (experimental) or placebo
(control)*
Experimental (n=8) Control (n=8)
Baseline Posttest Baseline Posttest
Kilocalorie intake 2534 + 284 2109 + 193 2400 + 286 1730 + 296
Protein intake (g) 93 + \0 91 + 12 91 + I 1 74 + 12
Carbohydrate intake (g) 322 + 40 256 + 33 290+ 29 202 + 31
Fiber intake (g) 23 + 3 16 + 2 22 +4 16 + 3
Fat intake (g) I 97 + 13 74 + 7 76 + 19 57 + 10
• Values are mean ± SEM
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Table 5: Analysis of variance summary table for serum glucose concentration fOllowing a
75 g OGlT after 12 weeks supplementation with CrCh (experimental) or
placebo (control)-






code (supp) 7.40 I 0.0003*














code (supp) 4.77 0.0030·
-
supplement 0.40 0.5386
! time 5.27 0.0390·
180 minutes
supp*time 0.02 0.9008
code (supp) 6.66 0.0008*
·Significance at p ~ 0.05
Values are gIven m mg/d1 Values are mean ± SEM
Table 6: Mean serum glucose concentration following a 75 g OGrr at baseline and after
1.212 weeks of supplemenlation with erC!) (experimental) or placebo (control)
Experimental (n=8) Control (n=8)
Baseline Posttest Baseline Posttest
ominutes 116 + 7 106 + 5 128 + 8 120 + 10
30 minutes 203 + 15 185 + 12 205 + 19 205 + 18
60 minutes 229 + 27 205 + 16 250 + 24 227 + 24
I 120 minutes 150 + 16 154 + 18 167 + 15 140 + 12
180 minutes 98 + 9 89 + 10 101 + 8 91 + 7
I 2,
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Table 7: Analysis ofvariance summary table for serum insulin concentration following a
75 g OGrr after 12 weeks supplementation with crCh (experimental) or
placebo (control)* -


























code (supp) 16.46 < 0.0001·
·Significance at p ~ 0.05
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Values are given In uIU/mi Values are mean ± SEM
Table 8: Mean serum insulin concentration foUowing a 75 g OGIT at baseline and after
1,212 weeks of supplementation with CTCh (experimental) Of-p-lacebo (coDtrol)
Experimental (n=8) Control (n=8)
Baseline Posttest Baseline Posttest
aminutes 27 + 5 24 + 6 27 + 5 19 + 2
30 minutes 96 + 15 82 + 16 89+ 21 63 + 10
60 minutes 132 + 26 126 + 33 107 + 20 71 + II
120 minutes 94 +24 79 + 21 95 + 19 71 + 23
180 minutes 46+ 14 45 + 16 34 + 6 27 + 8
\. 2·
Table 9: Analysis of variance summary table for percent glycosylated hemoglobin and
percent specific insulin binding after 12 weeks supplementation with CrCh
(experimental) or placebo (control)·
Source of Variance F value Probability
-




code (supp) 17.02 I < 0.0001·
supplement 0.00 0.9907
Percent Specific Insulin time 10.45 0.0060·
Binding
(per lOOmcg protein) supp*time 1.97 0.1825
code (supp) 0.36 0.9659
·Significance at P:5 0.05
Table 10: Mean percent glycosylated hemoglobin and percent specific insulin binding at
Baseline and after 12 weeks of supplementation wilh creb (experimental) or
placebo (control)·
Experimental (n=8) Conlrol (n=8)
Baseline Post1est Baseline Postte~
Glycosylated Hemoglobin 5.6 ± 0.1 5.9 ±0.1 6.0 ±0.1 I 6.4 ± 0.2
(%)
Specific Insulin Binding 1.7 ±0.2 1.4 ±0.2 2.0 ±0.1 1.1±0.1
(%)
(per 100mcg protein)




There was no significant time by group interaction in BMI. This was not
unexpected since the study was only 12 weeks in length and participants were instructed
to maintain a consistent diet throughout the duration of the study.
Dietary Intake
Even though participants were instructed to not change their diets, decreases in
total kilocalorie, carbohydrate, and fiber intakes were reported by the two groups.
Repeated measures analysis showed a significant time effect for total kilocalorie,
carbohydrate, and fiber intakes.
Serum Glucose
Chromium's aessentiality in humans was documented in 1977" as a result ofa
patient receiving inadequate long-tenn TPN (Anderson, 1997b~ Jeejeebhoy et a1., 1977).
Symptoms, such as glucose intolerance, were corrected upon the addition of chromium to
the TPN solution (Jeejeebhoy et al.) 1977). Since then, signs and symptoms of chromiwn
deficiency that are "routinely observed in the general population" include impaired
glucose tolerance, and decreased insulin binding (Anderson, 1997b).
Repeated measures analysis did not show a significant time by group interaction
for serum glucose concentrations. While a previous study involving 76 participants, of
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which 20 were glucose intolerant, demonstrated a significant decrease in fasting serum
glucose concentrations in glucose intolerant participants receiving 200 meg of chromium
cWoride per day for 3 monlhs (Anderson et aL, 1983), our study revealed DO such effect.
The 1983 study was a double-blind crossover design involving 76 participants, of which
13 males and 7 females were glucose intolerant (Anderson et aI., 1983). The participants
received 3 months ofchromium and then 3 months ofplacebo without a wash-out period
(Anderson et aI., 1983).
In our study, the mean glucose tolerance curve of the chromium group when
compared to the mean glucose tolerance cwve of the placeoo group showed no
significant improvement in glucose concentrations due to 12 weeks ofchromium
supplementation. These resuhs conflict with the flndings of the 1983 Anderson et al.
study, which demonslr81ed a significant improvement in glucose concentrations during an
OGTT for glucose intolerant participants who had received chromium supplementation
(Anderson et al., 1983).
A study thal had a similar sample size to ours but employed a crossover design
demonstrated that during an OGTI, glucose concentrations were significantly lower for
the hyperglycemic subjects after chromium supplementation than for comparable placebo
values (Anderson et al., 1991). The 1991 study involved two groups, a control group of6
healthy females and 3 healthy males aged 22-65 years and an experimental group of 5
hyperglycemic females and 3 hyperglycemic males aged 22-65 years (Anderson et aI.,
1991). The study looked at the effects of supplemental chromium on glucose and insulin
in participants consuming controlled low-chromium diets (Anderson et aI., 1991). The
supplementation consisted of200 meg per day ofchromium as chromium chJoride or a
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placebo. The supplementation periods lasted five weeks without a wash-out period
(Anderson et aI., 1991). Perhaps the larger sample size (Anderson et aI., 1983) and
crossover designs increased the potential for demonstrating significance in the 1983 and
1991 studies.
Serum Insulin
Repeated measures analysis did not show a significant time by group interaction
for serum insulin concentrations. A previous study demonstrated a significant
improvement in insulin concentrations "for the hyperglycemic group while receiving
chromium supplementation when compared to values obtained during the placebo
period," our study revealed no such effect on insulin concentrations (Anderson et aI.,
1991). The 1991 study observed during a four hour OGTT using I g glucoselkg body
weight, that the "sums of insulin values from 0 to 90 and from 0 to 240 minutes" of the
hyperglycemic participants significantly "decreased after chromium supplementation"
(Anderson et aI., 1991). This study had a similar sample size to ours but employed a
crossover design. The 1991 study involved two groups. a control group of 6 healthy
females and 3 healthy males aged 22-65 years and an experimental group of 5
hyperglycemic females and 3 hyperglycemic males aged 22-65 years (Anderson et al.,
1991). The study looked at the effects of supplemental chromium on glucose and insulin
in participants consuming controlled low-chromiwn diets (Anderson et aI., 1991). The
supplementation consisted of200 meg per day of chromium as chromium chloride or a
placebo. The supplementation periods lasted five weeks without a wash-out period
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(Anderson et al. 1991). Perhaps the observed significance in their study was a resuh of
their crossover experimental design.
Another study by Anderson et at that also used a crossover design and had a
larger sample size than our study did not have significantly improved serum insulin
concentrations from baseline (Anderson et aI., 1983). The 1983 study was a double-blind
crossover design involving 76 participants, of which 13 males and 7 females were
glucose intolerant (Anderson et aJ., 1983). The panicipants received 3 months of
chromium supplementation and then 3 months of placebo without a wash~out period
(Anderson el al., 1983). The chromium supplementation period consisted of 200 meg of
chromium per day as chromium chloride (Anderson et aI., 1983). However. as was
mentioned earlier about this study, there were significant improvements in serum glucose
concentrations. The improved serum glucose concentrations prompted Anderson and
colleagues to conclude that "'the insulin in the serum appeared to be more effective ...
foUowing Cr supplementation" and an "increase in insulin sensitivity would be a
prerequisite to reduced circulating levels" (Anderson et al., 1983). Since we did nol
observe any significant improvements in the serum glucose concentrations due to 12
weeks of chromium supplementation compared to the placebo, we cannot make the same
assumption regarding improved insulin sensitivity.
Glycosylated Hemoglobin
Repeated measures analysis did not show a significant time by group interaction
for the percentage of glycosylated hemoglobin. At baseline and pretest the mean percent
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glycosylated hemoglobin for both groups fell within the 4% to 8% range associated with
"persons without diabetes'\ (Lee & Nie~ 1996).
Glycosylated hemoglobin is a long-term indicator ofglucose tolerance (Lee &
Nieman, 1996). Improved glucose tolerance would lead to a reduced level ofcirculating
glucose, which would then correspond with a lower percentage ofglycosylated
hemoglobin. Since we did not observe a significant improvement in glucose tolerance, it
was not Wlexpeeted that the percent ofglycosylated hemoglobin did not significantly
change.
Percent Specific Insulin Binding
Repeated measures analysis did not show a significant time by group interaction
for mean percent specific insulin binding. No other chromium supplementation studies
have looked at percent specific insulin binding/WOrneg protein. Values for percent
specific insulin bindingll 00 mcg protein from studies with different objectives and
sample populations range from 0.93% to 2.51% for healthy participants (Bhathena ct aI.,
1989; Bhathena et al., 1995). At baseline and posttest the mean percent specific insulin
binding for both the chromium and placebo groups feB within the 0.93% to 2.51 % range.
CHAPTER V
SUMMARY, CONCLUSJONS) IMPLICAnONS, AND RECOM:MENDAnONS
Summary
This study investigated the effect of twelve weeks chromiwn supplementation at
200 mcg per day on fasting serum glucose concentration, fasting serum insulin
concentration, three-hour glucose tolerance curves, percent glycosylated hemoglobin, and
percent specific insulin binding in hyperglycemic men. This study folJowed a pretest-
posttest control group experimental design. Ten human participants in the control group
received a lactose placebo each day for twelve weeks. Ten participants in the
experimental group received a 200 meg chromium supplement as chromium chloride
each day over the same twelve week period. The two groups were randomly assigned as
control and experiment. Due to extraneous factors outside the focus of the study, four
participants were excluded from the data analysis leaving eight participants per group.
Twelve weeks ofchromium supplementation did not significantly affect fasting serum
glucose concentrations, fasting serum insulin concentrations. three-hour glucose tolerance
curves, percent glycosylated hemoglobin, or percent specific insulin binding in the
hyperglycemic men who participated in this study.
so
CODClusions
Five null hypotheses were developed for this study.
Ho 1: There will be no statistically significant effect of twelve weeks chromium
supplementation on fasting serum glucose concentrations in byperglycemic men.
There was no significant time by group interaction on fasting serum glucose
concentralions of hyperglycemic men receiving twelve weeks of chromium
supplementation and hyperglycemic men receiving twelve weeks of placebo
supplementation, therefore we failed to reject lhis null hypothesis.
~ 2: There will be no statistically significant effect of twelve weeks chromium
supplementation on fasting serum insulin concentrations in hyperglycemic men.
There was no significant time by group interaction on serum insulin
concentrations of hyperglycemic men receiving twelve weeks of chromium
supplementation and hyperglycemic men receiving twelve weeks of placebo
supplementation, therefore we failed to reject this null hypothesis.
H., 3: There will be no statistically significant effect oftwdve weeks chromium
supplementation on three-hour glucose tolerance curves of hyperglycemic men.
There was no significant time by group interaction on three-hour glucose
tolerance curves of hyperglycemic men receiving twelve weeks of chromium
supplementation and hyperglycemic men receiving twelve weeks of placebo
supplementation., therefore we failed to reject this null hypotbesis.
Ha 4: There will be no statisticaJly significant effect of twelve weeks chromium
supplementation on percent glycosy]ated hemoglobin of hyperglycemic meo.
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There was no significant time by group interaction on percent glycosylated
hemoglobin concentralions of hyperglycemic men receiving twelve weeks of
chromium supplementation and hyperglycemic men receiving twelve weeks of
placebo supplementation., therefore we failed to reject this null hypothesis.
Ho 5: There will be no statistically significant effect of twelve weeks chromium
supplemen[ation on percent specific insulin binding of hyperglycemic men.
There was no significant time by group interaction on percent specific insulin
binding of hyperglycemic men receiving twelve weeks of chromium
supplementation and hyperglycemic men receiving twelve weeks of placebo
supplementation, therefore we failed to reject this null hypothesis.
Assumptions
The following assumptions were made for this research:
1. It was assumed that the participants accurately filled out their one-week food
frequency questionnaire.
2. It was assumed that the participants took their supplements as directed.
3. It was assumed that the participants fasted for twelve hours before blood was
drawn.
4. It was assumed that the participants did not change their diet or exercise
patterns over the course of the study.
5. It was assumed that the participants did not take any other supplements
containing chromium over the course of the study.
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6. It was assumed that the participants did not undergo events causing lifestyle
changes, such as medication consumption and surgical events.
Limitations
1. The one week food frequencies were limited by the participants' knowledge of
sample size and food composition.
2. An inadequate data base for chromium limited analysis of chromium content
ofparticipants' diets.
3. The results of the study are relevant to this sample group limiting
extrapolation of results to the general population.
4. The results of this study are limited by outside factors affecting participants,
such as changes in medication and surgical events.
5. The results ofthe study are limited by the tendency for health conscious
individuals to volunteer to participate in this type of study.
Implications
This study involving hyperglycemic men and chromium supplementation as 200
mcg of chromium chloride per day for twelve weeks did not show a significant effect on
indicators ofglucose metabolism. Perhaps increasing sample size or pooling the two
groups and creating a crossover design would have enhanced our prospects for finding




In future studies I recommend doing away with the two-group design and pooling
participants into one group. Participant recruitment in Stillwater is difficult. When
participant numbers are low, a single study group with incorporation ofa crossover
period would create a more powerful experimental design. Although this design would
not make assumptions and limitations obsolete, it would make them less confounding. I
would increase contact with participants during the study to establish a closer tie with the
participants. In order to monitor compliance more closely, I recommend taking urine
samples. Urine samples would allow researchers to monitor compliance by comparing
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ARE YOU AT RISK FOR
DEVELOPING DIABETES?
Male Participants Wanted Who Are At Risk For Diabetes
Did you know that low intake of certain minerals may increase your risk
of developing diabetes?
Would you like to know if an adequate mineral intake lowers your risk of
developing diabetes?
You may be at risk of developing diabetes if you have one or more of the
following:
• Over 40 years of age
• Overweight
• Family history of diabetes
Volunteers who meet the study criteria will receive $300 for
completing the study.
For further information about the men's diabetes study please contact:
Janice R Hermann, PhD, ROllO







Men at risk for diabetes wanted for OSU nutrition study.
Would you like to know ifan adequate mineral intake lowers your risk of
developing diabetes?
You may be at risk of developing diabetes If you have one or more of the
following:
• Over 40 years of age
• Overweight
• Family history of diabetes
Men who meet the study criteria will receive $300 for completing the study. For
more information call xxx-xxx.
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-
Men at risk for diabetes wanted for OSU nutrition study. Factors increasing risk of
diabetes include family hislory of diabeles, overweight., over 40 years of age. Men





INDfVlDUAL CONSENT TO PARTICIPATE IN SCREENING PROCESS
68
1
Screening For Men's Diabctt§ Study: Effect of Chromium and Copper Supplementation on
Indicators of Diabetes in Men at Risk For Diabetes
"I. . hereby volunteer to panicipate in the ~reening for the above
titled study and authoriu or direct Janice R. Hennann, Ph.D., R.D./L.D., or associates of her
choosing, to perfonn the following treatment or procedure:·
J understand that:
(I) this is a screening for fastm~ and 2 hour glucose as cri leria for participating in the above
titled study which will measure the effects of chromiwn and copper supplementation on
indicators of diabetes in men at risk for diabetes;
(2) A licensed phlebolomlst will draw a fasling blood sample of 5 ml by venipuncru.re. After
which I will consume a surar drink containing 75 g ~Iucose. I will have Ii 5 ml blood samplt
drawn by venipW1c1ure by a Iicensed phlebotomist 120 minutes after consuming the &Iucose
drink.
(3) I may have slight discomfon and/or bruising from the venipUflCtuIc.
(4) after the two-hour blood sample I will receive a light meal for nulritionaJ suppon;
(5) my blood will only be used 10 measure blood glucose, and any remaining blood will be
discarded and no further tests will be run;
(6) I will complete a Health Questionnaire concerning health conditions. medication ~,
vitamin and mineral supplement use and exercise practices,
(7) all my records are confidential and my name will not be associated with any reports;
(8) 1 will receive a form with my personal laboratory results with accepted ranges for each
laboratory value. There will be a Statement at the bonom of the fonn indicating thaI I should s(:c
8 physician ifmy personal laboratory results are nOI In the accepted ranges.
(9) my participation in the screening is volUtltary, tMIlhere is no penalty for refusaJ 10
participate;
(l0) ] will be notified by the project dIrector If J meet the criteria to participate in lhe study;
(II) meeting lhe criteria for the study does not mean I am commined to participate i.Jl the study.
my participation in the study IS vo IUtltary , that there is no penally for refusal to panicipa\c. and
iliac I am free to withdraw my consent and participation in this project at any lime without
penalty after notifying the prOJeCI director;
(12) this research is benel1cial to the public in that the nsk of diabetes increases with 8[!.C and
low mineral intake.
(13) 1 may contact Dr JanIce Hermann at r40S) 269-1002 should I wish further informal ion.
may also contac1 Sharon l1acher. IRB Executive Secretary. 203 Whitehurst. Oklahoma Stall"
U oi versity. Stillwater. OK 740n. lelephone (405) 74'-1·6244
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I have read and fully understand the consent form. 1 si~n it freely and voluntarily. A copy has
been given to me.
Dat.e _ Time ~(a~.m~./~o~.m='.)
Signed _
Signature ofSubjecl
I certify that I have personally explained all elements of this form to the subject before requesting
the subject to sign iL.
Signed



















YesNo_I. Did you have any illness in the last month?
IF YES TO QUEST10N I
When where you ill? _
What type of il lness? _
Did you take any medication when you were ill? No
What type of medication did you take? _
Did you have a fever? No Yes _
Did you continue to take your supplement during the illness?
2. Did your exercise pattern change in the last month? No
IF YES TO QUESTION 2




INDIVIDUAL CONSENT TO PARTIClPATE IN RESEARCH
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Men's Diabetes Study: Effect of Chromium Supplementation
on Indicalors of Diabeles in Men at Risk for Diabetes
"I, , hereby volunteer to participate in the above titled study and
authorize or direct Janice R. Hennann, Ph.D., R.D,IL.D., or associates or assistants of her
choosing, to perform lhe following treatmenl or procedure."
I understand thac
(I) the purpose of the study is lhe measure the effect of chromium supplementation on
indicators of diabetes in prediabetic men with elevated insulin;
(2) [ will receive one month's of supplements containing ONE of the following.
(a) a placebo
(b) 200 ug chromium
(3) I will take one supplement a day wirh a meal for 24 weeks;
(4) ( will not take any other vitamin/mineral supplements or herbal/dielary supplements thaI
eonlain chromiwn other than those rhal are pan of this sludy;
(5) I will return each month to receive the next month's supplements,
(6) I will participate in a fasting blood collection and j-hour glucose tolerance tcst at the
beginning of the study, after 12 weeks supplementation and after 24 weeks
supplementalion. A licensed phlebotomisl will draw a fasting blood sample of20 ml by
venipuncture. After which rwill consume a glucose drink containing 75-g glucose. I
will have a 6 ml blood sample drawn by venipuncture by a licensed phlebotomist 30. 60,
120, and 1gO minutes after consuming the glucose drink.
(7) I may have slight discomfort and/or bruising from the venipuncture.
(8) after the 3-hour glucose tolerance tesl I wi II receive a light lunch for nutritional support.
(9) my blood will only be used for the study protocol, and any remaining blood tissue will be
discarded and no further tests will be run.
(10) routine measurements of my body weight will be taken al the beginning of the study,
after 12 weeks supplementation and after 24 weeks supplementation;
(II) 1will complete a Health Questionnaire concerning health conditions, medication use.
vitamin and mineral supplement use and exercise practices at the beginning of the study,
and a Follow-up Health Questionnaire after 12 weeks supplementation and after 24
weeks supplementation;
(12) I will complete a I-week food frequency questionnaHc at the beginning of the sludy,
after 12 weeks supplementation, and afler 7.4 weeks supplementation;
(13) as a reward for participation and as an Incenllve to complele the study, [ will receive
$150 after completing each of the three data colleclions for a total of $450; $150 after the
data collecllon at the beginning of the study, $1 SO after the data colleclion after 12 weeks
supplementation. and $1 50 after the data collCCllon after 24 weeks supplemenlallDn
(14) all my records are conrldenlial and lh~l m~ Ilame \Aill nOl be assocIated with any repons
or data records at the end of the siud y.
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(15) I will receive a fonn with my personal laboratory results with accepted ranges for each
laboralory value. There will be a statement allhe bonom of the fonn indicating thaI I
should see a physician ifmy personal laboratory results are nOl in the accepted ranges.
(16) my participation is voluntary, thaI lhere is no penalty for refusal (0 participare, Md that [
am free to withdraw my consent and participation In this project at any time without
penalty after notifying the project direclor;
(17) I will withdraw from the project if I need 10 begin laking medication for diabeles during
this study;
(18) this research is beneficial 10 (he public in (hal the risk diabetes increasing with age and
low mineral intake.
(19) I may contact Dr Janice Hennann at (405) 269-1002 shouJd [ wish further information.
may also oonlact Sharon Bacher, IRB Executive Secret.a.ry, 203 Whitehurst.. Oklahoma
State University, Stillwater, OK 74078; telephone (405) 744-6244 ..
I have read and fully understand the consenl form. I sign it freely and voluntarily. A copy has
been given to me.
Date _ Time ......>.:(8::.:..m=J..c.p""'.m""""',).
Signed--:::;-;-_-,-----_.,..-;:;----;-;- _
Signature 0 f Subjeet
[certify that I have personally explained all clements of this form to Ihe subject before
requesting lhe subject to sign it.
Signed -,------,-----,,.,...-__....,...-_---:------=------,- ---,-_








Sevt"n Dav food Frequen£Y Questionnaire
This questionnaire asks ~'OU about your consumption of foods and beverages over
the past week, The "Ho\~ Often" columns are (or day. week, or rarely/never. 'We
want you to think back (wer the pas: week and lell us how many limes (per day N
per week) you consumed each item. A medium serving. is in parentheses.
EXAMPLES:
Ale 1/2 grapefruit about [V,.'ICe laSI week.
Ate J large hamburger (our ume~ lasl week.
Drank 2 cups of whole mi II-. each da)
Type of Food
(Medium Serving)
l How Often Size-






Type of Food ~~'Oflen
,~T~(Medium Serving) I Da~ IWeek Rarel~'/
I I Never Iii
DAIRY FOODS I I I i--- f-----. IWhole milk (1 CUp. 80z)
2% milk (I cup. 8 Oz.)
._----




Skim milk (I cup. 8 oz) I -~- ..
Rice milk (J cup. 8 02)
I- I, ,
Soy milk (1 cup, 8 oz) -I' ,---,I




Cream, whipped (J Tbsp) I
"---'
Sour cream (I Tbsp) ,
Coffee cream (J Tbsp) ----1 ilee cream ('I, cup) -_.--~I




Frozen yogurt ('h cup) II
Yogurt (I cup) " !
Low fat yogurt (I cup)
---.-
)
Cottage cheese ('l2 cup) ! I-- ,....._L-_
Cream cheese (1 oz) ! I I,
Low fat cream cheese (I oz) I iI
Other cheese (1 slice or I Oz.) !
Low fat cheese (I slice or 1 oz) I I, , I
----I I
-.
Mar~arjne (I tsp) I
Butter (I tsp) -~_.- ,-I--- i
Reduced fat margarine (I tsp) I I ~--+--! --
--- -"_. L I iI I I.. ------~'-~
80
Type of Food How Orlen Siu
(Medium Serving) Da~' Week Rarelyl S M L
Never
FRUITS, FRUIT JUJCES







Apples, applesauce or pears
I
(I fresh, \12 cup) I
Applejuice (1)2 cup) !
Oranges ,
Orange juice (Y:z eup)
- I ,
Grapefruit (Y2 cup)
Grapefruit juice (Y:! cup)
Cranberry juice (\12 cup)
Other fruiljuices ell cup) I
Strawberries-fresh, frozen, or canned 1
(~~pl -r--i ,
Blueberries-fresh, frozen, or canned
('17 cup) ,
Peaches (1 fresh, Y2 cup canned) ,
Apricots (I fresh, YJ cup cilJUled)
Plums (l fresh, Y2 cup C3Med)
Honeydew melon (Yo melon)
Kiwi (I medium)
Fruit Cocktail ('l1 cup)
---,-r-MaJ1,RO (~ cup, or Y:! small) ---_.
Raspberries ('l1 cup) :
Blackberries (Y2 cup) !----+--- - "---Dried fruit (1/4 cup)
Pears (1 medium)
Pineapple chunks (Ih cup) i
Lemon juice (1/4 cup)




Type of Food How Often Siu








Tomato iuice (1/2 cup) I
- ,- j
Tomato sauce ('I, cup) ~
SpaRheni sauce ('I, cup)
Red chili sauce, taco sauce, or salsa
I(I Tbsp)
Tofu or soybeans (3-4 02.) ! !
String beans, Qreen beans el, cup) j!
Broccoli ('I, cup)
Cabbage (II, cup)
Cole slaw ('I, cup)
,
Cauliflower ('I, cup)
Brussels sprouts ('I, Cll p) I !
Carrots, raw ('I, carrot or 2-4 sticks)
Csrrots, cooked (lj, cup)
Com (1 ear or 'I, cup frozen or canned)
Peas (Yil cup fresh. frozen or canned)
Lima beans (~ cup frozen, or canned)
Mixed vegetables ('I, cup) I ,
Beans or lentils, baked or dried (II, cup)
,
Summer or yellow squash (YJcup)
Winter squash ('11 cup)
Zucchini (Y, cup)
Yam or sweet potato ('l1 Cll p)
Spinach, (cooked '12 cup, raw 1 cup)
lceberg lelluce. romai ne or lea f (I cup)
Celery (4" stick)
Beets ('1:1 cup)
Alfalfa sprouts (iI, cup) 1
Kale, mustard, or chard weens (Y, CUl!Lr~~-j
Vegetable, vegetable beef, minestrone I
or toma(<? soup (I cup) ~. __
Okra (Y~ cup) I,
Cucumber sl~ces ('11 cup) I !--,-'. I
--
C I r--- ----- -L_
2
Type of Food I How Often Sin





Collard greens (Y2 cup) i





Sweet peppers (If] cup)
Asparagus (Yi cup)
Jalapeno peppers (1/4 cup) I




Type of Food I How Oflen Size




, Chicken or turkey, roasted or broiled
Iwilh skin (3-4 oz) :
Chicken or lurkey, roasted or broiled
I
skinless (3-4 oz) I
Chicken. fried with skin (3-4 Oz.)
Bacon (2 slices)
Hot dogs (2) I
Low fat hot do~s (2)
-,-----
,
Sausage (2 pat! ies or 2 Jinks) - I
Bolog.na (J slice) r
Other processed luncheon meat (I slice)
Liver, chicken or beef (3-4 oz)
----
Hamburger, rep,ular (I patty, 3-4 Oz.) --




Pork, chops, roasts (3-4 01.) I
Lamb (3-4 01.) I
Beef, roast, sleak (3-4 01.)
- -----,-
Beef stew wi lh vege tables (l CllP) I
Ham (3-4 oz) I
TWla (3-4 Oz.) I
Tuna salad (112 cup) I
Fish, baked or broiled (3-4 oz)
'-'- . I I
Fish, fried or fl sh sandwich (3-4 oz-i I
Shrimp, Lobster, Scallops
Pizza (2 slices) .. - '-r-Mixed dishes with cheese (J cup)
Lasagna or meat pasta dishes (I cup~
-
Pot pie (I each) !
Eg~ beaters (y, cup)
Pork ribs (3 ribs) I
Deli meats (3 oz)
rGround turkey (3 oz) IIChicken salad (II cup) , !- ,- ,
Chil i (I cup) ! I
--- --
~- ------ ---~--
I IL--___ -- ----._-- -- - -- - ----- - -
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Type of Food How Often Siu
(Medium Serving) Day Week Rarely/ S M L
Never
BREADS, CEREALS, STARCHES
Cold breakfast cereal (I cup)
--
Cold breakfast cereal-fortified (I cup)
Cooked oauneal (I cup)
- f---
Other cooked breakfast cereal (I cup)
White bread (I slice) --
Pita bread (I piece)




Hamburger or hotdog bun (1 ) I
Muffin (1)
Biscuit (I)
Com bread, com muffin (1)
Brown rice (I cup)
White rice (Icup)
Spagheni noodles (1 cup)
Macaroni noodles (J cup)
Other pasta noodles (l cup)
Bulgar kasha, couscous (I cup)
Pancakes or waffles (2)
POLalOeS, french fries or fried (1/1 cup)
Potatoes, baked or boiled (1) --
Mashed potatoes (I cup)
Polato chips or com chips
(small bag or 1 oz) -
Saltine crackers (5)
Saltine crackers, low sodium (5)
Saltine crackers, fat free (5)
Other crackers (S) .
Other crackers, low fat (5)
----
Tortilla (I medium) ,
Graham cracker (3 medium)
Pretzels (15 small)
Trail mix (I cup)
--T- ---
------ --j
--- - t- ---t--I------ ~---------t-
-- --------- - - _____~ _L__
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Type of Food How Often Siu
(Medium Serving) D3~· Week Rarelyl S M L
Never
BEVERAGES
Regular soft. drink (1 )
Diet soft drink (1 ) I
Caffeine free soft. drink (I) [
Caffeine free, Diet soft drink ( I)
Lemonade or other non-carbonated
Idri nk (1 glass, bottle, or can)
Coffee (l cup)
Decaffeinated coffee (I cup)
~Tea(lcup) I I r
Herbal tea (1 cup)
Beer (I glass, bottle, or can)
Red wine (4 oz glass)
Pink wine (4 oz glass)
White wine (4 01. gIass)
Whiskey, gin, or other liquor I
(J drink or shot)
-
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Type of Food How Often Size
(Medium Sen'ing) Da~' IWeek RarelyJ S M L
Never
SWEETS, BAKED GOODS, MJSC. I II
Sorbet (Y2 cup) I ,
Granola bar (I small bar) I I
Chocolate (I small bar or I oz) I
Candy bar (1 small bar) ! -_._--
Candy without chocolate (1 01.)
Cookies, home baked (2)
Cookies, ready made (2) i
Brownies (2)
Dou~hnuts (2) ; I
!
-,'
Cake, home baked (I sl ice)
Cake, ready made (I slice)
,
Sweet roll, coffee cake, or other pastry
ready made (1 serving)
Sweet roll, coffee cake, or other pastry
Ihome baked (1 serving)
Pie, homemade (l slice) II
Pie, ready made (I slice) 1---Jam, jeHy, preserves, syrup, or Honey
(l Tbsp)
Peanut butter (I Thsp)
Popcorn (I cup) -
Popcorn, air popped (I cup) 1
Nuts (small packet or I oz) !
Bran, added to food (1 Tbsp)
Wheat ~erm (1 Tbsp) I
Chowder or cream soup (I cup)
--
I
Oil and vine~ar dressing (I .,TbsEL -
Soy sauce (t tsp)
,
--
Mayonnaise or other creamy salad ,
,
dressing (I Tbsp) I
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